Guideline on treating community-acquired pneumonia with Chinese patent medicines

Minghang Wang; Huiguo Liu; Yaolong Chen; Jiajie Yu; Jiangtao Lin; Zengtao Sun; Jiansheng Li; Gang Bai; Fuqiang Wen; Yang Xie; Jianxin Wang; Jiang Yang; Suyun Li

doi:10.1016/j.phrs.2023.106919

Guideline on treating community-acquired pneumonia with Chinese patent medicines

Pharmacol Res. 2023 Oct:196:106919. doi: 10.1016/j.phrs.2023.106919. Epub 2023 Sep 16.

Authors

Minghang Wang¹, Huiguo Liu², Yaolong Chen³, Jiajie Yu⁴, Jiangtao Lin⁵, Zengtao Sun⁶, Jiansheng Li¹, Gang Bai⁷, Fuqiang Wen⁴, Yang Xie¹, Jianxin Wang⁸, Jiang Yang⁹, Suyun Li¹⁰

Affiliations

¹ The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450046, China; Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases co-constructed by Henan province & Education Ministry of P.R. China, Zhengzhou 450000, China.
² Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China.
³ China Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730030, China; Chinese GRADE Center, Lanzhou, China.
⁴ Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu 610000, China; The Chinese Cochrane Center, Chengdu, China.
⁵ China-Japan Friendship Hospital, Beijing, China.
⁶ The Second Affiliated Hospital of Tianjin University of Chinese Medicine, Tianjin, China.
⁷ Nankai University, Tianjin 300193, China.
⁸ Standardization Project Management Office of China Association of Traditional Chinese Medicine, Beijing 100061, China.
⁹ Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases co-constructed by Henan province & Education Ministry of P.R. China, Zhengzhou 450000, China.
¹⁰ The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450046, China; Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases co-constructed by Henan province & Education Ministry of P.R. China, Zhengzhou 450000, China. Electronic address: lisuyun2000@126.com.

PMID: 37722517
DOI: 10.1016/j.phrs.2023.106919

Abstract

Community-acquired pneumonia (CAP) is one of the most common infectious diseases, and its morbidity and mortality increase with age. Resistance and mutations development make the use of anti-infective therapy challenging. Chinese patent medicines (CPMs) are often used to treat CAP in China and well tolerable. However, currently there are no evidence-based guideline for the treatment of CAP with CPMs, and the misuse of CPMs is common. Therefore, we established a guideline panel to develop this guideline. We identified six clinical questions through two rounds of survey, and we then systematically searched relevant evidence and performed meta-analyses, evidence summaries and GRADE decision tables to draft recommendations, which were then voted on by a consensus panel using the Delphi method. Finally, we developed ten recommendations based on evidence synthesis and expert consensus. For the treatment of severe CAP in adults, we recommend Tanreqing injection, Reduning injection, Xuebijing injection, Shenfu injection, and Shenmai injection respectively. For the treatment of non-severe CAP in adults, we recommend Tanreqing injection, Reduning injection, Lianhua Qingwen capsule/granule, Qingfei Xiaoyan Pill and Shufeng Jiedu capsule respectively. CPMs have great potential to help in the fight against CAP worldwide, but more high-quality studies are still needed to strengthen the evidence.

Keywords: Amygdalin (PubChem CID: 656516); Chinese patent medicines; Clinical practice guideline; Community-acquired pneumonia; Forsythoside A (PubChem CID: 5281773); GRADE; Ginsenoside Rg3 (PubChem CID: 9918693); Licochalcone A (PubChem CID: 5318998); Ligustilide (PubChem CID: 5319022); Luteolin (PubChem CID: 5280445); Quercetin (PubChem CID: 5280343); Resveratrol (PubChem CID: 445154); Saikosaponin A (PubChem CID: 167928); Skullcap (PubChem CID: 156595888).